Barclays analyst Luke Sergott raised the firm’s price target on Sotera Health (SHC) to $18 from $17 and keeps an Overweight rating on the shares. The firm says “no news is good news” on litigation as the California case count holds steady at 18.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: